Kyle Lahucik

Innoviva launches Nortiva Bio to revive Lyndra's LYNX oral drug delivery platform, starting with a Gates-funded monthly contraceptive targeting human trials in 2027.

The trend continues in which big-name venture investors band together to back new companies with an experimental medicine developed by another biotech.

Former Sanofi I&I exec Frédéric Marrache launches Bionyra with $165M to chase TL1A targets in IBD and eczema.

AbbVie strikes a $10.9B deal for Apogee, adding a long-acting IL-13 drug to its Humira-Skyrizi-Rinvoq I&I franchise.

Rapalogix Health, co-founded by Brent Saunders, raises $20M Series A to advance mTOR skincare science and prep for a 2028 IND in esthetic dermatology.

San Francisco biotech Osanni Bio, looking to build out a suite of ophthalmology- and cardiology-focused

Remix Therapeutics will go public via reverse merger with Passage Bio, taking its Nasdaq listing alongside a $100M placement as it advances mRNA degrader REM-422 in cancer.

SEC filings reveal how GSK's new CEO Luke Miels lined up the $10.6B Nuvalent buyout to land cancer drug neladalkib ahead of an FDA decision.

Biogen pauses or cancels most R&D programs from its $5.6B Apellis buyout and lays off staff, keeping its focus on Empaveli and Syfovre.

Lycia Therapeutics raises $75M Series D to advance protein degradation candidates for food allergy and Graves' disease toward early proof-of-concept data.